期刊文献+

Recombinant adenovirus-p53(Gendicine) sensitizes a pancreatic carcinoma cell line to radiation 被引量:6

Recombinant adenovirus-p53(Gendicine) sensitizes a pancreatic carcinoma cell line to radiation
在线阅读 下载PDF
导出
摘要 Objective: In this study, we examine the effects of recombinant adenovirus-p53 (rAd-p53) on the pancreatic carcinoma cell line SW1990. Specifically, we determine if expression of rAd-p53 sensitizes these cells to radiation. Methods: Following transfection of SW1990 cells with rAd-p53, we measured expression of P53, P21 and Bax by immunocytochemistry. Both transfected and control cell lines were irradiated with a range of doses, and the survival fractions (SF) were calculated. Dose survival cttrves were constructed and modeled for comparison. Results: Transfection of SW1990 cells with rAd-p53 resulted in increased expression of P53, P21 and Bax in a time-dependent manner. At 96 h after transfection, 89.92% of cells expressed P53, 56.8% expressed P21, and 76.50% expressed Bax. The SF following radiation was lower in the rAd-p53 transfected cells compared to the control cells, suggesting that rAd-p53 sensitizes SW1990 cells to radiation (Do for the experimental and control groups was 2.199 and 2.462, respectively). Conclusions: Use of the adenoviral vector is an effective means of transfecting SW1990 cells with wild-type P53, and this sensitizes the cell line to irradiation. This work suggests that combining rAd-p53 with radiation therapy in pancreatic cancer may be therapeutically beneficial. Objective: In this study, we examine the effects of recombinant adenovirus-p53 (rAd-p53) on the pancreatic carcinoma cell line SW1990. Specifically, we determine if expression of rAd-p53 sensitizes these cells to radiation. Methods: Following transfection of SW1990 cells with rAd-p53, we measured expression of P53, P21 and Bax by immunocytochemistry. Both transfected and control cell lines were irradiated with a range of doses, and the survival fractions (SF) were calculated. Dose survival cttrves were constructed and modeled for comparison. Results: Transfection of SW1990 cells with rAd-p53 resulted in increased expression of P53, P21 and Bax in a time-dependent manner. At 96 h after transfection, 89.92% of cells expressed P53, 56.8% expressed P21, and 76.50% expressed Bax. The SF following radiation was lower in the rAd-p53 transfected cells compared to the control cells, suggesting that rAd-p53 sensitizes SW1990 cells to radiation (Do for the experimental and control groups was 2.199 and 2.462, respectively). Conclusions: Use of the adenoviral vector is an effective means of transfecting SW1990 cells with wild-type P53, and this sensitizes the cell line to irradiation. This work suggests that combining rAd-p53 with radiation therapy in pancreatic cancer may be therapeutically beneficial.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第6期715-721,共7页 中国癌症研究(英文版)
基金 supported by Fujian Province Natural Science Foundation(No.2012J05139) Beijing Municipal Science & Technology Commission(No.Z111107058811021)
关键词 Pancreatic carcinoma recombinant adenovirus-p5 3 (rAd-p 5 3 TRANSFECTION RADIOSENSITIZATION Pancreatic carcinoma recombinant adenovirus-p5 3 (rAd-p 5 3 ) transfection radiosensitization
  • 相关文献

参考文献1

二级参考文献33

  • 1Jernal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
  • 2American Cancer Society. Cancer Facts and Figures 2009. Available from: URL: http://www.cancer.org/downloads/20og-s00809web.pdf.
  • 3Thomas A, Dajani K, Neoptolemos JP, et al, Adjuvant therapy in pancreatic cancer [J]. Dig Dis.2010; 28(4-5):684.-92..
  • 4Sultana A, Tudur Smith C, Cunninsham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008; 99:6-13.
  • 5Huguet F, Andre T, Hammel P, et al. Impact of radiochemotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase Ⅱ and Ⅲ studies. J Clin Oncol 2007; 25:326-31.
  • 6Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96:1183-90.
  • 7Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17. 1.
  • 8Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
  • 9Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-83.
  • 10Guerra C, Schuhmacher AJ, Canamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11:291-302.

共引文献2

同被引文献24

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部